To include your compound in the COVID-19 Resource Center, submit it here.

Astellas' peficitinib meets in Phase III for RA

Astellas Pharma Inc. (Tokyo:4503) reported top-line data from the Phase III RAJ4 trial in about 500 patients with rheumatoid arthritis who had an inadequate response to methotrexate showing that once-daily 100 and

Read the full 328 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers